Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats

Kakimoto, M.; Fujii, Moe; Sato, Ikumi; Honma, Koki; Nakayama, Hinako; Kirihara, Sora; Fukuoka, Taketo; Ran, Shang; Hirohata, Satoshi; Kitamori, Kazuya; Yamamoto, Sadaki; Watanabe, Shozo

doi:10.32725/jab.2023.009

Cited by 5 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 14 , 15 Emerging evidence indicates that Febuxostat has the potential to counteract oxidative stress, reduce lipid accumulation in the liver, and alleviate inflammation; factors that are fundamental to the onset and progression of NAFLD. 35 One trial incorporated Febuxostat in its design, aiming to evaluate the effects of xanthine oxidase inhibitors on MAFLD through the modulation of uric acid levels.…”

Section: Resultsmentioning

confidence: 99%

Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis

Hegazi,

Alalalmeh,

Shahwan

et al. 2024

DMSO

View full text Add to dashboard Cite

Background Non-alcoholic fatty liver disease (NAFLD) is a common disease and has been increasing in recent years. To date, no FDA-approved drug specifically targets NAFLD. Methods The terms “Non-alcoholic Fatty Liver Disease” and “NAFLD” were used in a search of ClinicalTrials.gov on August 24, 2023. Two evaluators independently examined the trials using predetermined eligibility criteria. Studies had to be interventional, NAFLD focused, in Phase IV, and completed to be eligible for this review. Results The ClinicalTrials.gov database was searched for trials examining pharmacotherapeutics in NAFLD. The search revealed 1364 trials, with 31 meeting the inclusion criteria. Out of these, 19 were finalized for evaluation. The dominant intervention model was Parallel. The most prevalent studies were in Korea (26.3%) and China (21.1%). The most common intervention was metformin (12.1%), with others like Exenatide and Pioglitazone accounting for 9.1%. Conclusion Therapeutics used to manage NAFLD are limited. However, various medications offer potential benefits. Further investigations are definitely warranted.

show abstract

Section: Resultsmentioning

confidence: 99%

Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis

Hegazi,

Alalalmeh,

Shahwan

et al. 2024

DMSO

View full text Add to dashboard Cite

show abstract

“…In the mouse model of MASH, both xanthine oxidase inhibitors appeared to alleviate hepatic steatosis and fibrosis [197,198]. In a pilot interventional study with febuxostat in patients with MAFLD, serum levels of ALT [before: 73.0 (69.8-117.8); after: 70.5 (57.5-94.5) IU/L, p = 0.040] and AST [before: 50.5 (40.8-69.8); after: 44.5 (34.8-60.8) IU/L, p = 0.018] were significantly decreased, and hepatic steatosis, as confirmed by conducting a histopathological examination, was improved [197].…”

Section: Xanthine Oxidase Inhibitorsmentioning

confidence: 99%

Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease

Bołdys,

Bułdak,

Maligłówka

et al. 2023

Medicina

View full text Add to dashboard Cite

Metabolic-associated Fatty Liver Disease is one of the outstanding challenges in gastroenterology. The increasing incidence of the disease is undoubtedly connected with the ongoing obesity pandemic. The lack of specific symptoms in the early phases and the grave complications of the disease require an active approach to prompt diagnosis and treatment. Therapeutic lifestyle changes should be introduced in a great majority of patients; but, in many cases, the adherence is not satisfactory. There is a great need for an effective pharmacological therapy for Metabolic-Associated Fatty Liver Disease, especially before the onset of steatohepatitis. Currently, there are no specific recommendations on the selection of drugs to treat liver steatosis and prevent patients from progression toward more advanced stages (steatohepatitis, cirrhosis, and cancer). Therefore, in this Review, we provide data on the clinical efficacy of therapeutic interventions that might improve the course of Metabolic-Associated Fatty Liver Disease. These include the drugs used in the treatment of obesity and hyperlipidemias, as well as affecting the gut microbiota and endocrine system, and other experimental approaches, including functional foods. Finally, we provide advice on the selection of drugs for patients with concomitant Metabolic-Associated Fatty Liver Disease.

show abstract

Role of ROS and autophagy in the pathological process of atherosclerosis

Zhu,

Liao,

Jiang

2024

J Physiol Biochem

View full text Add to dashboard Cite

Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats

Cited by 5 publications

References 44 publications

Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis

Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis

Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease

Role of ROS and autophagy in the pathological process of atherosclerosis

Contact Info

Product

Resources

About